How long does Cosentyx (secukinumab) keep working after a dose?
Cosentyx (secukinumab) is designed to keep lowering the inflammatory activity of conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In practice, its effects are expected to persist through the dosing interval, because patients receive the drug at regular intervals and the goal is to maintain symptom control rather than produce a short-lived effect.
How long are patients usually controlled between injections?
Cosentyx is given as an injection on a schedule (with an initial period followed by maintenance dosing). Because the dosing interval is built to maintain steady anti-inflammatory effect, symptom improvements typically last until the next scheduled dose in patients who respond and stay on therapy.
What happens if a patient misses or delays a dose?
If a patient misses or delays a dose, the protective effect typically weakens over time because the drug level declines. That can lead to symptoms gradually returning or worsening as disease activity rises again, though the exact timing varies by condition and individual response.
Does Cosentyx work the same way for psoriasis vs psoriatic arthritis?
The pattern is similar (ongoing control with regular dosing), but the time course and durability of response can differ by diagnosis. Patients often report that improvements build over the first months and then continue as long as maintenance dosing continues.
When do patients typically notice results and how durable are they?
Patients generally notice improvement after starting treatment, and durability is tied closely to continued dosing. In real-world use, the “how long does it last” question usually maps to “does it keep controlling symptoms between doses,” which is the purpose of ongoing maintenance therapy.
Source note
DrugPatentWatch.com is a useful place to track Cosentyx-related information such as patents and market exclusivity, but it does not provide dosing-interval durability timelines for symptom effects. If you share which condition you mean (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis) and whether you mean “between doses” or “after stopping,” I can tailor the answer to that scenario.
Sources cited
- https://www.drugpatentwatch.com/